Survival of Burkitt Lymphoma Depends on More than Just MYC

Share this content:
(ChemotherapyAdvisor) – The survival mechanisms of Burkitt lymphoma have been elucidated, according to an international team of researchers. This conclusion is based on a study entitled “Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis,” which was published online in Cancer Cell on August 14.

Burkitt lymphoma is a fast-growing, malignant B-cell-derived tumor formed in the germinal centers of several lymphatic tissues throughout the body. In normal B-cells, expression of a gene known as c-MYC leads to programmed cell death (apoptosis). However, when there are breaks in B-cell DNA, c-MYC is translocated to a new position in the genome. At this new position, overexpression of c-MYC leads to massive cell death. To play an oncogenic role, the proapoptotic activity of translocated c-MYC must be counterbalanced by survival signals.

In this study, the investigators aimed to determine the nature of these survival signals in Burkitt lymphoma-like tumors. The investigators hypothesized that survival signals in these tumors might be delivered by a protein known as PI3K, which causes mature B cells to overcome proapoptotic signals from c-MYC.

The investigators found that their hypothesis was indeed correct. In mouse germinal center B-cells, they observed that combining overexpressed c-MYC and PI3K activity led to the development of Burkitt lymphoma-like tumors. According to the investigators, these tumors are similar to human Burkitt lymphoma in histology, surface and other markers, and gene expression profile.

“These results and our finding of recurrent PI3K pathway activation in human BL indicate that deregulated c-MYC and PI3K activity cooperate in Burkitt lymphoma pathogenesis,” the investigators concluded.  


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs